纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗未行肾切除术且原发肾肿瘤可评估患者的CheckMate 214试验
CheckMate 214 3期试验的事后探索性分析,纳入108例未行肾切除术且原发肿瘤可评估的晚期肾细胞癌患者。纳武利尤单抗联合伊匹木单抗组(n=53)对比舒尼替尼组(n=55),总生存获益(HR 0.63,95%CI 0.40-1.0),客观缓解率更高(34% vs 15%,p=0.0041)。
要点
- 未行肾切除术患者中,纳武利尤单抗联合伊匹木单抗组中位总生存优于舒尼替尼组(HR 0.63,95%CI 0.40-1.0)。
- 客观缓解率联合组34% vs 舒尼替尼组15%(p=0.0041),中位缓解持续时间20.5 vs 14.1个月。
- 原发肾肿瘤直径缩小≥30%者联合组35% vs 舒尼替尼组20%。
核心结论
- 在未行肾切除术且原发肿瘤可评估的晚期肾细胞癌患者中,纳武利尤单抗联合伊匹木单抗对比舒尼替尼显示出生存获益和肾肿瘤缩小。
研究设计与样本
- 3期CheckMate 214试验的探索性事后分析,纳入108例未行肾切除术且原发肿瘤可评估的晚期肾细胞癌患者。
- 患者随机接受纳武利尤单抗联合伊匹木单抗(每3周一次共4剂,后续纳武利尤单抗单药)或舒尼替尼(每日用药4周,6周为一周期)。
- 在意向治疗人群最短随访4年的条件下评估总生存、无进展生存、客观缓解率和原发肿瘤缩小。
主要发现
- 未行肾切除术患者中,纳武利尤单抗联合伊匹木单抗组(n=53)总生存优于舒尼替尼组(n=55),风险比0.63(95%CI 0.40-1.0)。
- 客观缓解率联合组34% vs 舒尼替尼组15%(p=0.0041),中位缓解持续时间联合组20.5个月 vs 舒尼替尼组14.1个月。
- 两组最佳总体疗效均为部分缓解。
- 原发肾肿瘤直径缩小≥30%者联合组35% vs 舒尼替尼组20%。
- 安全性特征与全球研究人群一致。
局限性
- 该分析为探索性事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present an exploratory post hoc analysis from the phase 3 CheckMate 214 trial of first-line nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib in a subgroup of 108 patients with advanced renal cell carcinoma (aRCC) without prior nephrectomy and with an evaluable primary tumor, a population under-represented in clinical trials. Patients with clear cell aRCC were randomized to NIVO+IPI every 3 wk for four doses followed by NIVO monotherapy, or sunitinib every day for 4 wk (6-wk cycle). Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and primary tumor shrinkage were assessed. PFS and ORR were assessed per independent radiology review committee using RECIST version 1.1. With minimum study follow-up of 4 yr for intent-to-treat patients, OS favored NIVO+IPI (n = 53) over sunitinib (n = 55; hazard ratio 0.63, 95% confidence interval 0.40-1.0) among patients without prior nephrectomy. ORR was higher (34% vs 15%; p = 0.0041) and median duration of response was longer with NIVO+IPI versus sunitinib (20.5 vs 14.1 mo); the best overall response was partial response in either arm. A ≥30% reduction in the diameter of intact target renal tumors was achieved in 35% of patients with NIVO+IPI versus 20% with sunitinib. Safety was consistent with the global study population. In conclusion, in patients with aRCC without prior nephrectomy and with an evaluable primary tumor, NIVO+IPI showed survival benefits and renal tumor reduction versus sunitinib. This trial is registered at ClinicalTrials.gov as NCT02231749. PATIENT SUMMARY: In an exploratory analysis of a large global trial (CheckMate 214), we observed positive outcomes (both survival and tumor response to treatment) with nivolumab plus ipilimumab over sunitinib in a subgroup of patients with advanced kidney cancer who did not undergo removal of their primary kidney tumor. This subset of patients represents a population that has not been studied in clinical trials and for whom outcomes with new immunotherapy combination regimens are not yet known. We conclude that treatment with nivolumab plus ipilimumab offers these patients a survival benefit versus sunitinib, consistent with that observed in the overall study, as well as a notable kidney tumor reduction.
引用
- Albiges L, Tannir NM, Burotto M, et al. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Eur Urol. 2021. PMID: 34750035. doi:10.1016/j.eururo.2021.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。